Phase II trial of 5-fluorouracil, leucovorin, interferon-alpha-2a, and cisplatin as neoadjuvant chemotherapy for locally advanced esophageal carcinoma
Most patients with esophageal carcinoma present with locally advanced disease and a poor prognosis. Surgery or radiation provides palliation for locally advanced esophageal carcinoma. The role of neoadjuvant therapy remains to be defined. We administered neoadjuvant chemotherapy consisting of 5-fluo...
Gespeichert in:
| Veröffentlicht in: | Cancer 1996-06, Vol.77 (12), p.2432-2439 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2439 |
|---|---|
| container_issue | 12 |
| container_start_page | 2432 |
| container_title | Cancer |
| container_volume | 77 |
| creator | Temeck, B K Liebmann, J E Theodossiou, C Steinberg, S M Cook, J A Metz, D C Shawker, T H Allegra, C J Russo, A Pass, H I |
| description | Most patients with esophageal carcinoma present with locally advanced disease and a poor prognosis. Surgery or radiation provides palliation for locally advanced esophageal carcinoma. The role of neoadjuvant therapy remains to be defined. We administered neoadjuvant chemotherapy consisting of 5-fluorouracil (5-FU), leucovorin, interferon-alpha, and cisplatin to 11 patients with locally advanced disease.
Eleven patients with squamous cell or adenocarcinoma of the esophagus were treated peroperatively with two to three cycles of combination chemotherapy. Nine patients underwent resection with curative intent.
Six patients received three cycles of chemotherapy, and five received two. Dose reduction was necessary for two patients. One patient achieved a pathologic complete response, histologically confirmed. Of the eleven patients, two did not undergo surgery because of progressive disease during chemotherapy. Seven of the 9 patients relapsed after surgery and 2 have been disease free for 27 months.
The combination 5-FU leucovorin, interferon-alpha-2a, and cisplatin administered in a neoadjuvant setting resulted in a median survival of 11.8 months with a median time to relapse of 7 months. |
| doi_str_mv | 10.1002/(SICI)1097-0142(19960615)77:12<2432::AID-CNCR3>3.3.CO;2-F |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_78059520</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78059520</sourcerecordid><originalsourceid>FETCH-LOGICAL-p138t-fdc42ca9d24f00efb54ab4d4433d40a3747ff2812d885d95bea6123870306cd3</originalsourceid><addsrcrecordid>eNotUM1q3DAY1KElTdM-QkGnksBqq19b3pbC4jaJISSlzaG35Vv9dBVky5XswL5In7eG7GkYZphhBqEto2tGKf90-atruytGm5pQJvkla5qKVkxd1fWG8S9cCr7ZbLtvpL1vf4qvYi3W7cNnTq5foXNKqSZKit9v0NtSnhZacyXO0JmuJK10c47-_ThAcbjr8JQDRJw8VsTHOeU0ZzAhrnB0s0nPKYdhhcMwuexdTgOBOB6AcFhhGCw2oYwRpjBgKHhwCezT_AzDhM3B9Wk6uAzjEfuUcUwGYjxisItunMWupCXpj1vaDWQThtTDO_TaQyzu_Qkv0OP198f2ltw93HTt9o6MTOiJeGskN9BYLj2lzu-VhL20UgphJQVRy9p7rhm3WivbqL2DinGhaypoZay4QB9fYsec_s6uTLs-FONihGXCXHa1pqpRnC7GDyfjvO-d3Y059JCPu9OP4j9iRX8q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78059520</pqid></control><display><type>article</type><title>Phase II trial of 5-fluorouracil, leucovorin, interferon-alpha-2a, and cisplatin as neoadjuvant chemotherapy for locally advanced esophageal carcinoma</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>Wiley Online Library (Open Access Collection)</source><source>Alma/SFX Local Collection</source><creator>Temeck, B K ; Liebmann, J E ; Theodossiou, C ; Steinberg, S M ; Cook, J A ; Metz, D C ; Shawker, T H ; Allegra, C J ; Russo, A ; Pass, H I</creator><creatorcontrib>Temeck, B K ; Liebmann, J E ; Theodossiou, C ; Steinberg, S M ; Cook, J A ; Metz, D C ; Shawker, T H ; Allegra, C J ; Russo, A ; Pass, H I</creatorcontrib><description>Most patients with esophageal carcinoma present with locally advanced disease and a poor prognosis. Surgery or radiation provides palliation for locally advanced esophageal carcinoma. The role of neoadjuvant therapy remains to be defined. We administered neoadjuvant chemotherapy consisting of 5-fluorouracil (5-FU), leucovorin, interferon-alpha, and cisplatin to 11 patients with locally advanced disease.
Eleven patients with squamous cell or adenocarcinoma of the esophagus were treated peroperatively with two to three cycles of combination chemotherapy. Nine patients underwent resection with curative intent.
Six patients received three cycles of chemotherapy, and five received two. Dose reduction was necessary for two patients. One patient achieved a pathologic complete response, histologically confirmed. Of the eleven patients, two did not undergo surgery because of progressive disease during chemotherapy. Seven of the 9 patients relapsed after surgery and 2 have been disease free for 27 months.
The combination 5-FU leucovorin, interferon-alpha-2a, and cisplatin administered in a neoadjuvant setting resulted in a median survival of 11.8 months with a median time to relapse of 7 months.</description><identifier>ISSN: 0008-543X</identifier><identifier>DOI: 10.1002/(SICI)1097-0142(19960615)77:12<2432::AID-CNCR3>3.3.CO;2-F</identifier><identifier>PMID: 8640689</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Carcinoma - drug therapy ; Carcinoma - surgery ; Chemotherapy, Adjuvant ; Cisplatin - administration & dosage ; Combined Modality Therapy ; Esophageal Neoplasms - drug therapy ; Esophageal Neoplasms - surgery ; Female ; Fluorouracil - administration & dosage ; Humans ; Immunotherapy ; Interferon-alpha - administration & dosage ; Leucovorin - administration & dosage ; Male ; Middle Aged ; Recombinant Proteins ; Survival Analysis</subject><ispartof>Cancer, 1996-06, Vol.77 (12), p.2432-2439</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8640689$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Temeck, B K</creatorcontrib><creatorcontrib>Liebmann, J E</creatorcontrib><creatorcontrib>Theodossiou, C</creatorcontrib><creatorcontrib>Steinberg, S M</creatorcontrib><creatorcontrib>Cook, J A</creatorcontrib><creatorcontrib>Metz, D C</creatorcontrib><creatorcontrib>Shawker, T H</creatorcontrib><creatorcontrib>Allegra, C J</creatorcontrib><creatorcontrib>Russo, A</creatorcontrib><creatorcontrib>Pass, H I</creatorcontrib><title>Phase II trial of 5-fluorouracil, leucovorin, interferon-alpha-2a, and cisplatin as neoadjuvant chemotherapy for locally advanced esophageal carcinoma</title><title>Cancer</title><addtitle>Cancer</addtitle><description>Most patients with esophageal carcinoma present with locally advanced disease and a poor prognosis. Surgery or radiation provides palliation for locally advanced esophageal carcinoma. The role of neoadjuvant therapy remains to be defined. We administered neoadjuvant chemotherapy consisting of 5-fluorouracil (5-FU), leucovorin, interferon-alpha, and cisplatin to 11 patients with locally advanced disease.
Eleven patients with squamous cell or adenocarcinoma of the esophagus were treated peroperatively with two to three cycles of combination chemotherapy. Nine patients underwent resection with curative intent.
Six patients received three cycles of chemotherapy, and five received two. Dose reduction was necessary for two patients. One patient achieved a pathologic complete response, histologically confirmed. Of the eleven patients, two did not undergo surgery because of progressive disease during chemotherapy. Seven of the 9 patients relapsed after surgery and 2 have been disease free for 27 months.
The combination 5-FU leucovorin, interferon-alpha-2a, and cisplatin administered in a neoadjuvant setting resulted in a median survival of 11.8 months with a median time to relapse of 7 months.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Carcinoma - drug therapy</subject><subject>Carcinoma - surgery</subject><subject>Chemotherapy, Adjuvant</subject><subject>Cisplatin - administration & dosage</subject><subject>Combined Modality Therapy</subject><subject>Esophageal Neoplasms - drug therapy</subject><subject>Esophageal Neoplasms - surgery</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Interferon-alpha - administration & dosage</subject><subject>Leucovorin - administration & dosage</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Recombinant Proteins</subject><subject>Survival Analysis</subject><issn>0008-543X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNotUM1q3DAY1KElTdM-QkGnksBqq19b3pbC4jaJISSlzaG35Vv9dBVky5XswL5In7eG7GkYZphhBqEto2tGKf90-atruytGm5pQJvkla5qKVkxd1fWG8S9cCr7ZbLtvpL1vf4qvYi3W7cNnTq5foXNKqSZKit9v0NtSnhZacyXO0JmuJK10c47-_ThAcbjr8JQDRJw8VsTHOeU0ZzAhrnB0s0nPKYdhhcMwuexdTgOBOB6AcFhhGCw2oYwRpjBgKHhwCezT_AzDhM3B9Wk6uAzjEfuUcUwGYjxisItunMWupCXpj1vaDWQThtTDO_TaQyzu_Qkv0OP198f2ltw93HTt9o6MTOiJeGskN9BYLj2lzu-VhL20UgphJQVRy9p7rhm3WivbqL2DinGhaypoZay4QB9fYsec_s6uTLs-FONihGXCXHa1pqpRnC7GDyfjvO-d3Y059JCPu9OP4j9iRX8q</recordid><startdate>19960615</startdate><enddate>19960615</enddate><creator>Temeck, B K</creator><creator>Liebmann, J E</creator><creator>Theodossiou, C</creator><creator>Steinberg, S M</creator><creator>Cook, J A</creator><creator>Metz, D C</creator><creator>Shawker, T H</creator><creator>Allegra, C J</creator><creator>Russo, A</creator><creator>Pass, H I</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>19960615</creationdate><title>Phase II trial of 5-fluorouracil, leucovorin, interferon-alpha-2a, and cisplatin as neoadjuvant chemotherapy for locally advanced esophageal carcinoma</title><author>Temeck, B K ; Liebmann, J E ; Theodossiou, C ; Steinberg, S M ; Cook, J A ; Metz, D C ; Shawker, T H ; Allegra, C J ; Russo, A ; Pass, H I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p138t-fdc42ca9d24f00efb54ab4d4433d40a3747ff2812d885d95bea6123870306cd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Carcinoma - drug therapy</topic><topic>Carcinoma - surgery</topic><topic>Chemotherapy, Adjuvant</topic><topic>Cisplatin - administration & dosage</topic><topic>Combined Modality Therapy</topic><topic>Esophageal Neoplasms - drug therapy</topic><topic>Esophageal Neoplasms - surgery</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Interferon-alpha - administration & dosage</topic><topic>Leucovorin - administration & dosage</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Recombinant Proteins</topic><topic>Survival Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Temeck, B K</creatorcontrib><creatorcontrib>Liebmann, J E</creatorcontrib><creatorcontrib>Theodossiou, C</creatorcontrib><creatorcontrib>Steinberg, S M</creatorcontrib><creatorcontrib>Cook, J A</creatorcontrib><creatorcontrib>Metz, D C</creatorcontrib><creatorcontrib>Shawker, T H</creatorcontrib><creatorcontrib>Allegra, C J</creatorcontrib><creatorcontrib>Russo, A</creatorcontrib><creatorcontrib>Pass, H I</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Temeck, B K</au><au>Liebmann, J E</au><au>Theodossiou, C</au><au>Steinberg, S M</au><au>Cook, J A</au><au>Metz, D C</au><au>Shawker, T H</au><au>Allegra, C J</au><au>Russo, A</au><au>Pass, H I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase II trial of 5-fluorouracil, leucovorin, interferon-alpha-2a, and cisplatin as neoadjuvant chemotherapy for locally advanced esophageal carcinoma</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>1996-06-15</date><risdate>1996</risdate><volume>77</volume><issue>12</issue><spage>2432</spage><epage>2439</epage><pages>2432-2439</pages><issn>0008-543X</issn><abstract>Most patients with esophageal carcinoma present with locally advanced disease and a poor prognosis. Surgery or radiation provides palliation for locally advanced esophageal carcinoma. The role of neoadjuvant therapy remains to be defined. We administered neoadjuvant chemotherapy consisting of 5-fluorouracil (5-FU), leucovorin, interferon-alpha, and cisplatin to 11 patients with locally advanced disease.
Eleven patients with squamous cell or adenocarcinoma of the esophagus were treated peroperatively with two to three cycles of combination chemotherapy. Nine patients underwent resection with curative intent.
Six patients received three cycles of chemotherapy, and five received two. Dose reduction was necessary for two patients. One patient achieved a pathologic complete response, histologically confirmed. Of the eleven patients, two did not undergo surgery because of progressive disease during chemotherapy. Seven of the 9 patients relapsed after surgery and 2 have been disease free for 27 months.
The combination 5-FU leucovorin, interferon-alpha-2a, and cisplatin administered in a neoadjuvant setting resulted in a median survival of 11.8 months with a median time to relapse of 7 months.</abstract><cop>United States</cop><pmid>8640689</pmid><doi>10.1002/(SICI)1097-0142(19960615)77:12<2432::AID-CNCR3>3.3.CO;2-F</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 1996-06, Vol.77 (12), p.2432-2439 |
| issn | 0008-543X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78059520 |
| source | MEDLINE; Access via Wiley Online Library; Wiley Online Library (Open Access Collection); Alma/SFX Local Collection |
| subjects | Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma - drug therapy Carcinoma - surgery Chemotherapy, Adjuvant Cisplatin - administration & dosage Combined Modality Therapy Esophageal Neoplasms - drug therapy Esophageal Neoplasms - surgery Female Fluorouracil - administration & dosage Humans Immunotherapy Interferon-alpha - administration & dosage Leucovorin - administration & dosage Male Middle Aged Recombinant Proteins Survival Analysis |
| title | Phase II trial of 5-fluorouracil, leucovorin, interferon-alpha-2a, and cisplatin as neoadjuvant chemotherapy for locally advanced esophageal carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T00%3A26%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%20II%20trial%20of%205-fluorouracil,%20leucovorin,%20interferon-alpha-2a,%20and%20cisplatin%20as%20neoadjuvant%20chemotherapy%20for%20locally%20advanced%20esophageal%20carcinoma&rft.jtitle=Cancer&rft.au=Temeck,%20B%20K&rft.date=1996-06-15&rft.volume=77&rft.issue=12&rft.spage=2432&rft.epage=2439&rft.pages=2432-2439&rft.issn=0008-543X&rft_id=info:doi/10.1002/(SICI)1097-0142(19960615)77:12%3C2432::AID-CNCR3%3E3.3.CO;2-F&rft_dat=%3Cproquest_pubme%3E78059520%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78059520&rft_id=info:pmid/8640689&rfr_iscdi=true |